Bipartisan Senate bill seeks to build vigilance around foreign companies making drugs in US

A bipartisan U.S. Senate bill unveiled in July 2026 seeks to increase scrutiny of foreign companies making drugs in the United States, driven by concerns about national security and public health risks from overreliance on foreign manufacturing and investment.

The Pharmaceutical Investment Oversight and Accountability Act, introduced by Senators Elizabeth Warren (D‑Mass.), Rick Scott (R‑Fla.), and Kirsten Gillibrand (D‑N.Y.), would require the Federal Trade Commission (FTC) and the Department of Treasury—with input from CFIUS—to produce an annual report to Congress examining foreign investment in the U.S. pharmaceutical industry.

The bill would require regulators to assess how foreign manufacturing and capital affect the U.S. drug supply, including shifts of domestic plants overseas, and the impact of foreign stakes in DNA sequencing and biotech infrastructure, with the goal of improving transparency and vigilance around foreign‑owned drugmakers operating in the U.S.

Sources:

Warren, Rick Scott Lead Bipartisan Push Urging ...

Senate bill seeks to curb US reliance on China in drug ...

Lawmakers want U.S. to probe reliance on foreign-made ...

Peters Introduces Bipartisan Bill to Help Address National Security Threat Created by U.S. Dependence on Foreign Drug Manufacturers | U.S. Senator Gary Peters of Michigan

Warren, Smith Reintroduce Bill to Boost U.S. Pharmaceutical Manufacturing Capacity and End Over-Reliance on Foreign Countries for Critical Drugs

LIVE: Senate Committee Hearing Examines Foreign Control of ...

Scott, Colleagues Reintroduce Bill to Encourage America’s Pharmaceutical Independence — U.S. Senator Tim Scott of South Carolina

Bipartisan push grows in Senate to expose where America's drugs ...

Democrats unveil global drug safety bill

Cotton, Colleagues Introduce Bill to End U.S. Dependence on Chinese-Manufactured Pharmaceuticals | U.S. Senator Cotton of Arkansas

I

Grassley, Colleagues Introduce Bill to Allow U.S. Consumers Access to Lower-cost Prescription Drugs | The United States Senate Committee on Finance

Text - GovInfo

S.2665 - 119th Congress (2025-2026): A bill to amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical drugs of increased demand, and for other purposes.